surgery partners inc. holds annual meeting, approves key proposals

Surgery Partners, Inc. (NASDAQ:SGRY), a $2.94 billion market cap healthcare company with 13.54% revenue growth over the last twelve months, held its annual meeting of stockholders today, where several significant proposals were approved. The meeting took place as scheduled, with stockholders voting on key items, according to a press release statement. According to InvestingPro data, while the company isn’t currently profitable, analysts expect positive earnings this year.

The election of Class I directors was one of the primary agenda items. Stockholders re-elected John A. Deane, Teresa DeLuca, M.D., and Wayne S. DeVeydt as Class I directors, each to serve until the 2028 annual meeting. The voting results showed strong support, with Deane receiving 106,384,986 votes in favor, DeLuca 102,050,559, and DeVeydt 105,187,839. Votes withheld were 9,461,903 for Deane, 13,796,330 for DeLuca, and 10,659,050 for DeVeydt. The company maintains a "GOOD" overall financial health score according to InvestingPro analysis.

Another key proposal was the advisory vote on executive compensation, which was approved on a non-binding basis. The results included 96,577,058 votes for, 19,241,638 against, and 28,193 abstentions.

Additionally, stockholders approved the 2025 Omnibus Incentive Plan, receiving 101,740,477 votes in favor, 13,957,369 against, and 149,043 abstentions. The plan is designed to provide incentives to employees and align their interests with those of the stockholders.

The ratification of Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025, was also on the agenda. This proposal passed with 122,065,302 votes for, 30,124 against, and 7,400 abstentions.

The meeting’s outcomes reflect the company’s strategic direction and commitment to governance. Surgery Partners, Inc., based in Brentwood, Tennessee, operates in the general medical and surgical hospitals sector. The company is incorporated in Delaware and its common stock is listed on the Nasdaq Global Select Market under the ticker symbol SGRY. With a beta of 1.94, the stock shows higher volatility than the market. Discover more insights and detailed analysis in the comprehensive Pro Research Report, available exclusively on InvestingPro.

In other recent news, Surgery Partners has been the subject of several analyst reviews and strategic developments. The company reported first-quarter results for 2025 that aligned with expectations, confirming its full-year guidance for revenue and adjusted EBITDA, which anticipates an approximate 10% increase at the midpoint. KeyBanc Capital Markets maintained a Sector Weight rating, noting modest EBITDA outperformance and robust same-store revenue growth, while Benchmark reiterated a Buy rating with a $35 price target, citing improved cash flow and declining financial leverage. Cantor Fitzgerald also maintained an Overweight rating, emphasizing the company’s stable trends and potential undervaluation amid ongoing strategic developments.

UBS analysts reiterated a Buy rating, with a $34 price target, amid discussions about the potential sale of AMSURG, which could influence the valuation of Surgery Partners. Meanwhile, Leerink Partners adjusted its price target to $34 from $36, maintaining an Outperform rating, highlighting consistent patient volumes and effective cost management. Bain Capital’s nonbinding proposal to acquire Surgery Partners at $25.75 per share remains a focal point for investors, with industry analysts suggesting it could be accepted. Surgery Partners’ strategic positioning to mitigate macroeconomic concerns, such as minimal exposure to Medicare and Medicaid changes, further supports its financial stability. As the company continues to navigate strategic moves and potential deals, these developments remain closely watched by investors and market analysts.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.